Evaluation of the effectiveness of additional risk minimisation measures (aRMM) materials for Xeljanz® (tofacitinib) in Europe via a survey of healthcare professionals (HCPs): A non interventional (NI) post authorisation safety study (PASS)

First published 29/09/2021

Last updated 02/07/2024

EU PAS number:

EUPAS43143

Study

Finalised

Download as PDF

Documents

Study protocol

Initial protocol

A3921334 Evaluation of the effectiveness of addiitonal risk minimisation (aRMM) materials for Xeljanz (tofacitibib) in Europe via a survey of healthcare professionals (HCPs)

English (6.34 MB - PDF)View document

Updated protocol

A3921334_PROTOCOL- XELJANZ HCP SURVEY CLEAN_V3.0_28MAR2022

First published: 22/02/2024

English (1.46 MB - PDF)View document

Study results

Study report

A3921334_FINAL STUDY REPORT_ 08DEC2022

English (1012.5 KB - PDF)View document

Other information

ENCePP Seal

ENCePP Seal documents

Evaluation of the effectiveness of additional risk minimisation measures (aRMM) materials for Xeljanz® (tofacitinib) in Europe via a survey of healthcare professionals (HCPs): A non interventional (NI) post authorisation safety study (PASS)

Secondary tabs

Share this page